Table 2 P-RFA vs. PEI: Results of meta-analysis
Variables | No. of studies furnishing data | Results | RR/WMD (95% CI) P-value | I2 | |
|---|---|---|---|---|---|
RFA | PEI | ||||
Baseline characteristics: | |||||
Child-Pugh grade of liver dysfunction A B | 624,26–30 624,26–30 | 71% 24% | 70% 26% | 1.05 (0.97, 1.13), 0.44 0.92 (0.74, 1.15), 0.43 | 0% 0% |
Tumour size, cm (mean ± SEM) | 426–28,30 | 2.62 ± 0.33 | 2.47 ± 0.35 | 0.13 (0.01, 0.25),0.03 | 0% |
Single nodule | 624,26–30 | 59% | 55% | 1.04 (0.94, 1.50), 0.44 | 17% |
Follow-up duration, months (mean ± SEM) | 326–28 | 25 ± 6.2 | 23.6 ± 5.6 | 0.97 (-1.32, 3.3), 0.4 | 0% |
Efficacy: | |||||
Survival 1 year 2 years 3 years 4 years | 526–30 526–30 427–30 229,30 | 96% 86% 73% 62% | 91% 75% 58% 51% | 1.04 (1.007, 1.08), 0.02 1.13 (1.06, 1.20), <0.001 1.28 (1.12, 1.45), <0.001 1.24 (1.05,1.48), <0.001 | 0% 0% 12.6% 0% |
Local recurrence | 426–29 | 7% | 22% | 0.37 (0.23, 0.59), 0.000 | 0% |
Disease-free survival 1 year 2 years 3 years | 326–28 326–28 227,28 | 80% 61% 40% | 70% 42% 19% | 1.13 (1, 1.28), 0.04 1.31 (1.06, 1.61), 0.013 2.1 (1.35, 3.23), 0.001 | 0% 0% 0% |
Tumour complete response | 424,26–28 | 93.5% | 84.5% | 1.10 (1.04, 1.17), 0.01 | 0% |
Remote intra-hepatic recurrence | 526–30 | 43% | 45% | 0.97 (0.82, 1.11), 0.56 | 0% |
Safety: | |||||
Total complications | 624,26–30 | 19.2% | 10.5% | 2.55 (1.8, 3.65), <0.001 | 0% |
Major complications | 424,28–30 | 4.1% | 2.7% | 1.85 (0.68, 5.01); 0.22 | 0% |